Christine Durand
Infectious Disease · Baltimore, MDNPI 1730225095
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $51,555 of the $52,622 with a category attached, or 98.0%. Every reported general payment came from a single manufacturer, Gilead. Among infectious disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $3095.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$53K
Across 22 payments — averaging $6484.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$112K
- Viiv Healthcare Company$30K
What the payments were for
- Consulting fees$51,55598%
- Travel & lodging$8402%
- Food & beverage$2270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 17 | $52,622 |
How this compares
$52,622 in reported general payments places this provider in the 95th percentile of 289 infectious disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 45 | $171,265 |
| CabenuvaCabotegravir/Rilpivirine | 16 | $97,539 |
| TivicayDolutegravir Sodium | 15 | $50,121 |
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $48,991 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $37,172 |
| PrezcobixDarunavir/Cobicistat | 13 | $36,328 |
| ValacyclovirValacyclovir Hcl | 15 | $692 |
| Ketoconazole | 12 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $52,622 | $220,25762 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 289 infectious disease providers in Maryland.
Other infectious disease in Baltimore
- Robert RedfieldBaltimore$779K
- Luciana BorioBaltimore$671K
- Mark SulkowskiBaltimore$240K
- Jonathan ZenilmanBaltimore$202K
- Robert EdelmanBaltimore$125K
- Kjell WibergBaltimore$113K
- Myron LevineBaltimore$51K
- Robert BollingerBaltimore$50K
- Richard BergBaltimore$47K
- Justin OrtizBaltimore$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.